173 related articles for article (PubMed ID: 10991855)
1. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell K
Antimicrob Agents Chemother; 2000 Oct; 44(10):2747-51. PubMed ID: 10991855
[TBL] [Abstract][Full Text] [Related]
2. Comparative in vitro activities of ABT-773 against aerobic and anaerobic pathogens isolated from skin and soft-tissue animal and human bite wound infections.
Goldstein EJ; Citron DM; Merriam CV; Warren Y; Tyrrell K
Antimicrob Agents Chemother; 2000 Sep; 44(9):2525-9. PubMed ID: 10952607
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activity of ertapenem and 11 other antimicrobial agents against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell K; Fernandez H
J Antimicrob Chemother; 2001 Nov; 48(5):641-51. PubMed ID: 11679553
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez H
Antimicrob Agents Chemother; 2002 Mar; 46(3):866-70. PubMed ID: 11850275
[TBL] [Abstract][Full Text] [Related]
5. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.
Goldstein EJ; Citron DM; Merriam CV; Tyrrell K; Warren Y
Antimicrob Agents Chemother; 1999 Jun; 43(6):1475-9. PubMed ID: 10348774
[TBL] [Abstract][Full Text] [Related]
6. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tissue bite infections in humans.
Goldstein EJ; Citron DM; Merriam CV
Antimicrob Agents Chemother; 1999 Jun; 43(6):1469-74. PubMed ID: 10348773
[TBL] [Abstract][Full Text] [Related]
7. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
8. Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans.
Goldstein EJ; Citron DM; Hunt Gerardo S; Hudspeth M; Merriam CV
Antimicrob Agents Chemother; 1998 May; 42(5):1127-32. PubMed ID: 9593139
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
Fritsche TR; Kirby JT; Jones RN
Diagn Microbiol Infect Dis; 2004 Jul; 49(3):201-9. PubMed ID: 15246511
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans.
Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
Antimicrob Agents Chemother; 1997 Jul; 41(7):1552-7. PubMed ID: 9210683
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
Gales AC; Jones RN
Diagn Microbiol Infect Dis; 2000 Jan; 36(1):19-36. PubMed ID: 10744364
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.
Gales AC; Jones RN; Andrade SS; Pereira AS; Sader HS
Braz J Infect Dis; 2005 Oct; 9(5):348-56. PubMed ID: 16410885
[TBL] [Abstract][Full Text] [Related]
13. Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents.
Goldstein EJ; Citron DM
Antimicrob Agents Chemother; 1993 May; 37(5):1150-3. PubMed ID: 8390810
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
Petersen PJ; Jacobus NV; Weiss WJ; Sum PE; Testa RT
Antimicrob Agents Chemother; 1999 Apr; 43(4):738-44. PubMed ID: 10103174
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.
Betriu C; Rodríguez-Avial I; Sánchez BA; Gómez M; Alvarez J; Picazo JJ;
Antimicrob Agents Chemother; 2002 Mar; 46(3):892-5. PubMed ID: 11850282
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
Boucher HW; Wennersten CB; Eliopoulos GM
Antimicrob Agents Chemother; 2000 Aug; 44(8):2225-9. PubMed ID: 10898710
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.
Projan SJ
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):219S-223S; discussion 224S-228S. PubMed ID: 11001329
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of faropenem and 11 other antimicrobial agents against 405 aerobic and anaerobic pathogens isolated from skin and soft tissue infections from animal and human bites.
Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez HT
J Antimicrob Chemother; 2002 Sep; 50(3):411-20. PubMed ID: 12205068
[TBL] [Abstract][Full Text] [Related]
19. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
J Antimicrob Chemother; 1998 Mar; 41(3):391-6. PubMed ID: 9578167
[TBL] [Abstract][Full Text] [Related]
20. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-susceptible and -resistant pneumococci.
Hoellman DB; Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2000 Apr; 44(4):1085-8. PubMed ID: 10722519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
